Company research / ZVSA
ZyVersa Therapeutics, Inc. (ZVSA)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.
Annual financials
| Period ended | TTM to 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-12 | 2021-12-31 |
|---|---|---|---|---|---|---|
| R&D Expense | $911.9K | $1.11M | $1.78M | $3.21M | n/a | n/a |
| Operating Income | -$24.65M | -$25.49M | -$9.14M | -$107.75M | n/a | n/a |
| Net Income | -$24.49M | -$24.95M | -$9.41M | -$98.30M | n/a | n/a |
| EPS (Diluted) | n/a | -$4.18 | -$8.48 | -$1089.70 | n/a | n/a |
| Total Assets | $742.2K | $347.9K | $20.60M | $22.11M | n/a | $77.14M |
| Total Liabilities | $14.87M | $12.73M | $12.08M | $11.04M | n/a | $3.65M |
| Shareholders' Equity | -$14.12M | -$12.39M | $8.52M | $11.07M | $99.68M | -$2.26M |
| Cash & Equivalents | n/a | n/a | n/a | n/a | n/a | $928.4K |
| Operating Cash Flow | -$4.14M | -$5.11M | -$7.52M | -$8.72M | n/a | n/a |
| Shares Outstanding | 8.10M | 8.10M | 2.51M | 402.2K | n/a | n/a |
| Weighted Average Diluted Shares | n/a | 5.96M | 1.11M | 97.5K | n/a | n/a |
| EPS (Basic) | n/a | -$4.18 | -$8.48 | -$1089.70 | n/a | n/a |